Incidence of malignancy in primary Sjögren's syndrome in a Chinese cohort

Rheumatology

Volumn 49, Issue 3, 2009, Pages 571-577

  Zhang, Wen ^a   Feng, Sheng ^b   Yan, Shumin ^a   Zhao, Yan ^a   Li, Mengtao ^a   Sun, Jian ^a   Zhang, Feng Chun ^a   Cui, Quancai ^a   Dong, Yi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Lymphoma; Malignancy; Sj gren's syndrome

Indexed keywords

ADULT; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CHINA; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HYPERGAMMAGLOBULINEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHADENOPATHY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MUCOEPIDERMOID TUMOR; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PAROTID ENLARGEMENT; PAROTID GLAND TUMOR; PRIORITY JOURNAL; SJOEGREN SYNDROME; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THYMOMA; THYROID CARCINOMA; TONGUE CARCINOMA; UTERINE CERVIX CANCER;

ADULT; CHINA; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; SJOGREN'S SYNDROME;

EID: 77950536950     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep404     Document Type: Article

References (29)

1. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
2. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
3. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
4. Kassan SS, Thomas TL, Moutsopoulos HM et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
5. Kauppi M, Pukkala E, Isomäki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8:201-4.
6. Valesini G, Priori R, Bavoillot D et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol 1997;24:2376-80.
7. Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology 1999;38:245-53.
8. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72.
9. Lazarus MN, Robinson D, Mak V, Møller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology 2006;45:1012-5.
10. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803.
11. Pariente D, Anaya JM, Combe B et al. Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med 1992;1:337-42.
12. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999;42:1765-72.
13. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
14. Voulgarelis M, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome. Isr Med Assoc J 2001;3:761-6.
15. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
16. Song SZ, Zhou JC. Lymphoma. In: Deng J, Yang C, Yang T, Wang Z, Zhang Z, Li J, eds Deng Jiadong's text book of clinical hematology. Shanghai: Shanghai Science and Technology Publishing Press, 2001:1030-5.
17. Liu JE, Xiang YB, Jin F et al. Cancer incidence trends in urban Shanghai, 1972-1999 (in Chinese). Zhong Liu 2004;24:11-5.
18. Anderson LA, Gadalla S, Morton LM et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125:398-405.
19. Masaki Y, Sugai S. Lymphoproliferative disorders in Sjögren's syndrome. Autoimmun Rev 2004;3:175-82.
20. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68.
21. Pillemer SR. Lymphoma and other malignancies in primary Sjögren's syndrome. Ann Rheum Dis 2006;65:704-6.
22. Jonsson R, Nginamau E, Szyszko E, Brokstad KA. Role of B cells in Sjögren's syndrome - from benign lymphoproliferation to overt malignancy. Front Biosci 2007;12: 2159-70.
23. Tazi I, Rachid M, Benchekroun S. Sjögren's syndrome associated with multiple myeloma. Singapore Med J 2008; 49:e215-6.
24. Gál I, Zeher M. Sjögren's syndrome and multiple myeloma. Orv Hetil 2000;141:2087-9.
25. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2000;54:692-701.
26. Levy Y, Afek A, Sherer Y et al. Malignant thymoma associated with autoimmune diseases: a retrospective study Malignancies in SS and review of the literature. Semin Arthritis Rheum 1998; 28:73-9.
27. Insler MS, Shelin RG. Sjögren's syndrome and thymoma. Am J Ophthalmol 1987;104:90-1.
28. Reed JH, Neufing PJ, Jackson MW et al. Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol 2007;148:153-60.
29. Sisto M, Lisi S, Lofrumento D, D'Amore M, Scagliusi P, Mitolo V. Autoantibodies from Sjögren's syndrome trigger apoptosis in salivary gland cell line. Ann N Y Acad Sci 2007;1108:418-25.